DDInter604 DDInter1925
Drospirenone is a synthetic progestin commonly found in the popular oral contraceptive, Yaz in combination with [Ethinyl estradiol]. Most recently, it was approved by both Health Canada and the FDA in combination with [Estetrol] as an oral contraceptive therapy.[L33199,L33174] Aside from its contraceptive effects, drospirenone is used with estrogens to control acne and premenstrual dysphoric disorder (PMDD). Drospirenone has been the subject of widespread safety concern due to the possibility of an increased risk of venous thromboembolism associated with its use.[A182543,A182552] In 2012, however, a safety statement by the FDA concluded that the increase in the risk of thromboembolism resulting from the use of drospirenone remains unclear, as studies regarding this risk are conflicting. Some studies have demonstrated a significantly increased risk and some demonstrating no risk of thrombo
Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collaboration with Genentech launched a broad development program.
Drospirenone {u} (Compound) causes {v} (Side Effect) Skin disorder
Skin disorder {u} (Side Effect) is caused by {v} (Compound) Vemurafenib
Drospirenone {u} (Compound) resembles {v} (Compound) Progesterone
Progesterone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vemurafenib
Drospirenone {u} (Compound) resembles {v} (Compound) Medroxyprogesterone acetate
Medroxyprogesterone acetate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vemurafenib
Drospirenone {u} (Compound) causes {v} (Side Effect) Skin disorder
Skin disorder {u} (Side Effect) is caused by {v} (Compound) Etoricoxib
Etoricoxib {u} (Compound) resembles {v} (Compound) Vemurafenib
Drospirenone {u} (Compound) resembles {v} (Compound) Progesterone
Progesterone {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Vemurafenib
Drospirenone {u} (Compound) resembles {v} (Compound) Medroxyprogesterone acetate
Medroxyprogesterone acetate {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Vemurafenib
Drospirenone {u} (Compound) resembles {v} (Compound) Flurandrenolide
Flurandrenolide {u} (Compound) resembles {v} (Compound) Dexamethasone
Dexamethasone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vemurafenib
Drospirenone {u} (Compound) causes {v} (Side Effect) Skin disorder
Skin disorder {u} (Side Effect) is caused by {v} (Compound) Mirabegron
Mirabegron {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vemurafenib
Drospirenone {u} (Compound) causes {v} (Side Effect) Angiopathy
Angiopathy {u} (Side Effect) is caused by {v} (Compound) Lidocaine
Lidocaine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vemurafenib
Drospirenone {u} (Compound) resembles {v} (Compound) Medroxyprogesterone acetate
Medroxyprogesterone acetate {u} (Compound) downregulates {v} (Gene) MTHFD2
MTHFD2 {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Drospirenone (Compound) causes Skin disorder (Side Effect) and Skin disorder (Side Effect) is caused by Vemurafenib (Compound)
Drospirenone (Compound) resembles Progesterone (Compound) and Progesterone may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib
Drospirenone (Compound) resembles Medroxyprogesterone acetate (Compound) and Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib
Drospirenone (Compound) causes Skin disorder (Side Effect) and Skin disorder (Side Effect) is caused by Etoricoxib (Compound) and Etoricoxib (Compound) resembles Vemurafenib (Compound)
Drospirenone (Compound) resembles Progesterone (Compound) and Progesterone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Drospirenone (Compound) resembles Medroxyprogesterone acetate (Compound) and Medroxyprogesterone acetate (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Drospirenone (Compound) resembles Flurandrenolide (Compound) and Flurandrenolide (Compound) resembles Dexamethasone (Compound) and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib
Drospirenone (Compound) causes Skin disorder (Side Effect) and Skin disorder (Side Effect) is caused by Mirabegron (Compound) and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Vemurafenib
Drospirenone (Compound) causes Angiopathy (Side Effect) and Angiopathy (Side Effect) is caused by Lidocaine (Compound) and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Vemurafenib
Drospirenone (Compound) resembles Medroxyprogesterone acetate (Compound) and Medroxyprogesterone acetate (Compound) downregulates MTHFD2 (Gene) and MTHFD2 (Gene) is upregulated by Vemurafenib (Compound)